Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Farmacosmo SpAMIL:COSMO +1.27%34 EV-to-EBITDA is 70.91 as of Aug. 04, 2026, which is 136% above its 10-year median of 30.07. GuruFocus rates MIL:COSMO with a GF Score™ of 34/100 and a GF Value™ of €0.76 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 508 Healthcare Providers & Services companies, Farmacosmo SpA ranks worse than 93.9% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Farmacosmo SpA's enterprise value is €24.96 Mil.
Farmacosmo SpA's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €0.35 Mil. Therefore, Farmacosmo SpA's EV-to-EBITDA for today is 70.91.
The historical rank and industry rank for Farmacosmo SpA's EV-to-EBITDA or its related term are showing as below:
MIL:COSMO'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -770.79 Med: 30.07 Max: 106.04
Current: 70.91
During the past 6 years, the highest EV-to-EBITDA of Farmacosmo SpA was 106.04. The lowest was -770.79. And the median was 30.07.
MIL:COSMO's EV-to-EBITDA is ranked worse than 93.9% of 508
companies
in the Healthcare Providers & Services industry
Industry Median: 11.02
vs MIL:COSMO: 70.91
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Farmacosmo SpA's PE Ratio (TTM) for today is calculated as:
Farmacosmo SpA's share price for today is €0.477.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Farmacosmo SpA's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.114.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Farmacosmo SpA's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Pharmaceutical Retailers subindustry, Farmacosmo SpA's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Farmacosmo SpA EV-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Farmacosmo SpA's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Farmacosmo SpA's EV-to-EBITDA falls into.
Farmacosmo SpA's current Enterprise Value is €24.96 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Farmacosmo SpA's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €0.35 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Farmacosmo SpA (MIL:COSMO) has a EV-to-EBITDA of 70.91 as of Aug. 04, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Farmacosmo SpA. This is 136% above median its historical median of 30.07. According to the industry distribution chart, Farmacosmo SpA ranks #477 out of 508 companies in the Healthcare Providers & Services industry, placing it in the top 93.9%.
Is Farmacosmo SpA's EV-to-EBITDA too high?
Farmacosmo SpA's current EV-to-EBITDA of 70.91 is 136% above median its 10-year median of 30.07. The Healthcare Providers & Services industry median EV-to-EBITDA is 11.02. Farmacosmo SpA's value of 70.91 is 543.5% above this industry median. Based on the distribution chart, Farmacosmo SpA ranks #477 out of 508 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Farmacosmo SpA has a GF Score™ of 34/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Farmacosmo SpA's EV-to-EBITDA compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Farmacosmo SpA ranks #477 out of 508 companies for EV-to-EBITDA. This places Farmacosmo SpA in the lower half of its industry. The industry median EV-to-EBITDA is 11.02. Farmacosmo SpA's value of 70.91 is 543.5% above this benchmark. While the company's 10-year median is 30.07 vs. the industry median of 11.02, Farmacosmo SpA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Healthcare Providers & Services company?
The median EV-to-EBITDA among Healthcare Providers & Services companies is 11.02, based on 508 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Farmacosmo SpA's current EV-to-EBITDA of 70.91 is 543.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Farmacosmo SpA. For the Healthcare Providers & Services industry, the median EV-to-EBITDA is 11.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Farmacosmo SpA's current EV-to-EBITDA is 70.91, which is 136% above median its own 10-year median of 30.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Farmacosmo SpA stock overvalued right now?
Based on GuruFocus' analysis, Farmacosmo SpA (MIL:COSMO) is currently considered Possible Value Trap. The stock's GF Value™ is €0.76, compared to a current price of €0.48 — trading 37.2% below its estimated fair value. The current EV-to-EBITDA is 70.91, which is 136% above median its 10-year median of 30.07 and 543.5% above the Healthcare Providers & Services industry median of 11.02. Farmacosmo SpA's overall GF Score™ is 34/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Farmacosmo SpA (MIL:COSMO), the current EV-to-EBITDA is 70.91 as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Farmacosmo SpA (MIL:COSMO) Overvalued in 2026?
Based on GuruFocus' analysis, Farmacosmo SpA stock appears to be undervalued.
The current stock price of €0.48 is trading 37.2% below its estimated GF Value™ of €0.76.
GuruFocus considers Farmacosmo SpA to be Possible Value Trap.
Key valuation signals for MIL:COSMO:
EV-to-EBITDA: 70.91 (136% above median its 10-year median of 30.07)
GF Value™: €0.76 vs. price of €0.48 (37.2% below fair value)
Industry Position: 543.5% above the Healthcare Providers & Services median (#477 of 508)
No single metric tells the full story. See the MIL:COSMO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Farmacosmo SpA is a wellness e-commerce company active in the Health, Pharma, and Wellness industry, authorized by the Italian Ministry of Health to sell pharmaceutical products online. In particular, the company offers parapharmaceutical products, vitamins and food supplements, dietetic products, medical devices, cosmetic products, personal hygiene products, hair care products, dental care products, skincare products, perfumes, home and baby items.
34GF Score
Get the complete analysis for MIL:COSMO
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:COSMO has been successfully added to your 
